JP7810466B2 - 線維芽細胞または線維芽細胞様細胞を従来型２型樹状細胞にリプログラミングするための方法 - Google Patents

線維芽細胞または線維芽細胞様細胞を従来型２型樹状細胞にリプログラミングするための方法

Info

Publication number
JP7810466B2
JP7810466B2 JP2024508173A JP2024508173A JP7810466B2 JP 7810466 B2 JP7810466 B2 JP 7810466B2 JP 2024508173 A JP2024508173 A JP 2024508173A JP 2024508173 A JP2024508173 A JP 2024508173A JP 7810466 B2 JP7810466 B2 JP 7810466B2
Authority
JP
Japan
Prior art keywords
cells
ebp
cdc2
fibroblasts
fibroblast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024508173A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023176806A1 (https=
Inventor
雄太郎 熊谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Advanced Industrial Science and Technology AIST
Original Assignee
National Institute of Advanced Industrial Science and Technology AIST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute of Advanced Industrial Science and Technology AIST filed Critical National Institute of Advanced Industrial Science and Technology AIST
Publication of JPWO2023176806A1 publication Critical patent/JPWO2023176806A1/ja
Application granted granted Critical
Publication of JP7810466B2 publication Critical patent/JP7810466B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024508173A 2022-03-18 2023-03-14 線維芽細胞または線維芽細胞様細胞を従来型２型樹状細胞にリプログラミングするための方法 Active JP7810466B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022043701 2022-03-18
JP2022043701 2022-03-18
PCT/JP2023/009757 WO2023176806A1 (ja) 2022-03-18 2023-03-14 線維芽細胞または線維芽細胞様細胞を従来型２型樹状細胞にリプログラミングするための方法

Publications (2)

Publication Number Publication Date
JPWO2023176806A1 JPWO2023176806A1 (https=) 2023-09-21
JP7810466B2 true JP7810466B2 (ja) 2026-02-03

Family

ID=88023842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508173A Active JP7810466B2 (ja) 2022-03-18 2023-03-14 線維芽細胞または線維芽細胞様細胞を従来型２型樹状細胞にリプログラミングするための方法

Country Status (5)

Country Link
US (1) US20250195569A1 (https=)
EP (1) EP4477749A4 (https=)
JP (1) JP7810466B2 (https=)
CN (1) CN118871574A (https=)
WO (1) WO2023176806A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020513191A (ja) 2017-04-05 2020-05-07 アスガード セラピューティクス エービー 細胞を樹状細胞または抗原提示細胞にリプログラムするための組成物、その方法および使用
WO2021069672A1 (en) 2019-10-10 2021-04-15 Asgard Therapeutics Ab Composition for reprogramming cells into plasmacytoid dendritic cells or interferon type i-producing cells, methods and uses thereof
WO2021105234A1 (en) 2019-11-25 2021-06-03 Asgard Therapeutics Ab Compositions for reprogramming cells into dendritic cells type 2 competent for antigen presentation, methods and uses thereof
WO2021133775A1 (en) 2019-12-23 2021-07-01 University Of Florida Research Foundation, Incorporated Immunotherapy for direct reprogramming of cancer cells into immune cells/antigen presenting cells/dendritic cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3385373A1 (en) * 2017-04-05 2018-10-10 Centro de Neurociências e Biologia Celular Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020513191A (ja) 2017-04-05 2020-05-07 アスガード セラピューティクス エービー 細胞を樹状細胞または抗原提示細胞にリプログラムするための組成物、その方法および使用
WO2021069672A1 (en) 2019-10-10 2021-04-15 Asgard Therapeutics Ab Composition for reprogramming cells into plasmacytoid dendritic cells or interferon type i-producing cells, methods and uses thereof
WO2021105234A1 (en) 2019-11-25 2021-06-03 Asgard Therapeutics Ab Compositions for reprogramming cells into dendritic cells type 2 competent for antigen presentation, methods and uses thereof
WO2021133775A1 (en) 2019-12-23 2021-07-01 University Of Florida Research Foundation, Incorporated Immunotherapy for direct reprogramming of cancer cells into immune cells/antigen presenting cells/dendritic cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Frontiers in Immunology，2018年，Vol.9, No.2714，pp.1-14

Also Published As

Publication number Publication date
EP4477749A4 (en) 2025-06-04
WO2023176806A1 (ja) 2023-09-21
US20250195569A1 (en) 2025-06-19
EP4477749A1 (en) 2024-12-18
CN118871574A (zh) 2024-10-29
JPWO2023176806A1 (https=) 2023-09-21

Similar Documents

Publication Publication Date Title
JP7778708B2 (ja) 多能性幹細胞からナチュラルキラー細胞を産生するための方法
ES2549155T3 (es) Células iPS obtenidas a partir de células NKT y células NKT obtenidas a partir de las mismas
CN110088272B (zh) 用于将细胞重编程为树突状细胞或抗原呈递细胞的组合物、其方法和用途
US20250084145A1 (en) Method for establishing pluripotent stem cells bearing genes encoding antigen specific t cell receptor
CN110914411A (zh) 干扰素引发的浆细胞样树突细胞
EP4410965A1 (en) Method for producing t cell
JP2023502318A (ja) 細胞を再プログラム化して形質細胞様樹状細胞またはｉ型インターフェロン産生細胞に変換する組成物、その方法および用途
US20230183645A1 (en) Method for producing regenerated t cells via ips cells
US20130171115A1 (en) Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene
TW202421780A (zh) T細胞的製造方法
EP4324917A1 (en) Cell bank composed of ips cells for introducing t cell receptor gene
JP7743980B2 (ja) ヒトＴ細胞由来ｉＰＳ細胞由来の細胞傷害性Ｔ細胞
JP7810466B2 (ja) 線維芽細胞または線維芽細胞様細胞を従来型２型樹状細胞にリプログラミングするための方法
CN119452076A (zh) 免疫细胞的产生
WO2021206104A1 (ja) がんの処置に用いるｐｐ６５含有人工アジュバントベクター細胞
US20250345430A1 (en) Pluripotent stem cell-derived immune cell inducing chemotaxis for heterogeneous immune cells
KR102184341B1 (ko) 역분화 만능 유도세포 유도용 조성물
EP4177344A1 (en) Novel transplantation cells having reduced immunogenicity
EP4722349A1 (en) Pluripotent stem cell-derived cd4-positive t cells, method for production thereof, and use thereof
WO2024102777A2 (en) Compositions and method for expansion of embryonic stem cells
WO2023229013A1 (ja) ＩＬ－１２ｐ７０を恒常的に産生する増殖性ミエロイド細胞の製造方法
Lee Building a Cancer Vaccine for Immunotherapy Through Transdifferentiation of Cancer Cells into Macrophage-like Cells
HK1186977A (en) Use of mesenchymal stem cells (msc) expressing suicide gene to perform cell-mediated cancer gene therapy

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240906

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20241106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260115

R150 Certificate of patent or registration of utility model

Ref document number: 7810466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150